Altitude Life Science Ventures
Philosophy is to focus on life science markets with strong demand and growth potential, and then back the highest-quality entrepreneurs in
Business Model: B2B
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Altitude Life Science Ventures Information
Geographic Data
Address:
City: Kirkland
State: WA
Zip: 98033
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Philosophy is to focus on life science markets with strong demand and growth potential, and then back the highest-quality entrepreneurs in those markets to build defensible, strong, and long-term businesses. build portfolio among attractive life science sectors in a manner that balances risk while maximizing potential synergies and ultimate returns. Our focus is on opportunities in biotechnology, medical devices, and diagnostics, but we are continually responsive to the best areas for investing in order to adapt to changing market conditions. Invest in companies that: * are pursuing substantial and growing market opportunities * possess a unique and proprietary technology, with a clear competitive advantage * are early-stage opportunities * have or will attract strong management * have a strong investment syndicate * offer a defined path to liquidity
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 9/2011 | Kythera Biopharmaceuticals | Series D | 0 |
| 7/2018 | Omniome | Series B | 0 |
| 6/2019 | Encoded Therapeutics | Series C | 104M |
| 6/2010 | Constellation Pharmaceuticals | Series B | 22.3M |
| 6/2011 | Constellation Pharmaceuticals | Series B | 15M |
| 4/2017 | Sienna Biopharmaceuticals | Series B | 0 |
| 3/2020 | Cero Therapeutics | Series A | 0 |
| 7/2021 | Ring Therapeutics | Series B | 117M |
| 11/2009 | Cambrios Technologies | Series D | 14.5M |
| 3/2018 | UNITY Biotechnology | Series C | 55M |
| 10/2022 | Neumora Therapeutics | Series B | 0 |
| 11/2021 | Generate Biomedicines | Series B | 0 |
| 8/2009 | Constellation Pharmaceuticals | Series A | 17.2M |
| 1/2017 | Vir Biotechnology | Venture Round | 150M |
| 5/2008 | Kythera Biopharmaceuticals | Series C | 0 |
| 10/2016 | BlackThorn Therapeutics | Series A | 40M |
| 7/2006 | Kythera Biopharmaceuticals | Series B | 30M |
| 1/2020 | Omniome | Series C | 60M |
| 10/2010 | Siluria Technologies | Series A | 13.3M |
| 10/2019 | Nuvation Bio | Series A | 275M |
| 1/2021 | Tessera Therapeutics | Series B | 0 |
| 6/2015 | Pulmatrix | Post-IPO Equity | 10M |
| 3/2013 | Receptos | Series B | 30M |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 12/2015 | Effector Therapeutics | Series B | 40M |
| 8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 7/2012 | Siluria Technologies | Series C | 30M |
| 4/2022 | Ansa Biotechnologies | Series A | 68M |
| 8/2018 | Millendo Therapeutics | Venture Round | 30M |
| 1/2016 | Millendo Therapeutics | Series B | 0 |
| 10/2021 | Neumora Therapeutics | Series A | 0 |
| 4/2022 | Tessera Therapeutics | Series C | 0 |
| 4/2019 | Vividion Therapeutics | Series B | 82M |
| 10/2021 | Mozart Therapeutics | Series A | 0 |
| 4/2016 | Sienna Biopharmaceuticals | Series A | 34M |
| 9/2011 | Siluria Technologies | Series B | 20M |
| 7/2009 | Limerick BioPharma | Series C | 15M |
| 6/2008 | Limerick BioPharma | Venture Round | 15.2M |
| 5/2007 | Arete Therapeutics | Series A | 35M |
| 6/2020 | Sana Biotechnology | Series A | 700M |
| 6/2019 | BlackThorn Therapeutics | Series B | 76M |
| 3/2019 | Beam Therapeutics | Series B | 135M |
| 4/2022 | Tessera Therapeutics | Series C | 0 |
| 4/2022 | Ansa Biotechnologies | Series A | 0 |
| 11/2021 | Generate Biomedicines | Series B | 0 |
| 10/2021 | Mozart Therapeutics | Series A | 0 |
| 10/2021 | Neumora Therapeutics | Series A | 0 |
| 8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
| 7/2021 | Ring Therapeutics | Series B | 0 |
| 1/2021 | Tessera Therapeutics | Series B | 0 |
| 1/2021 | Dice Therapeutics | Series C | 0 |
| 6/2020 | Sana Biotechnology | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
